← All trials
NCT05364840
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 7, 2022
- Primary completion
- Jan 31, 2023
- Completion date
- Feb 28, 2023
- First posted
- May 6, 2022
- Last posted
- Oct 31, 2022
- Enrollment
- 58
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sorrento Therapeutics, Inc.Lead sponsor
- Sorrento Therapeutics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.